Submission of Half Yearly Financial Results - September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.3 pts more than Nifty Microcap 250 and 18.8 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mahamaya Lifesciences Ltd (BSE SME, Scrip Code 544611) reported its H1 FY26 (April-September 2025) results. Standalone revenue from operations rose to Rs 16,306.37 lakhs from Rs 14,623.12 lakhs in H1 FY25, an ~11.5% YoY growth. Profit after tax grew to Rs 852.56 lakhs (vs Rs 725.25 lakhs), translating to an EPS of Rs 4.80 (vs Rs 4.48). Total income stood at Rs 16,433 lakhs. The auditor (N Naresh & Co) issued an unmodified limited review report on both standalone and consolidated results. Consolidated PAT was Rs 836.88 lakhs (vs Rs 724.65 lakhs). The company is in the agro crop protection and healthcare products business.
Modest top-line growth of around 11-12% and steady PAT growth of ~17% suggest stable operations, but the negative operating cash flow of around Rs 690 lakhs (standalone) and rising working capital needs (inventories up 62%, receivables nearly doubled, short-term borrowings up 52%) indicate that earnings are not yet translating into cash, which could pressure liquidity and weigh on the stock in the near term.